PMGC Holdings Inc. ELAB
1.14 USD -0.13 (-10.24%)
Regular-session close
1.17 +0.03 +2.63%
After hours · Nov 20, 7:09 PM ET
1.14 Day range 1.35
1.14 52-week range 1,291.20
- YTD
- -99.68%
- 1 year
- -99.90%
News
globenewswire.com NorthStrive Defense Tech Announces Successful Completion of Technical Validation and Update to Acquire GPS-Denied Drone Navigation Technology NEWPORT BEACH, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC, a wholly owned subsidiary of PMGC Holdings Inc. (the “Company”) (NASDAQ: ELAB), today announced that it has…
globenewswire.com PMGC Holdings Inc. [NASDAQ: ELAB] Announces Successful Combination of Two Aerospace Manufacturing Companies into a Single California Location, Enhancing Manufacturing and Operational Efficiency and Reducing Costs PMGC Holdings Inc. [NASDAQ: ELAB] Announces Successful Combination of Two Aerospace Manufacturing Companies into a Single California Location, Enhancing Ma
globenewswire.com PMGC Holdings Inc. [NASDAQ: ELAB] Reports Record Q3 Revenue, Up 785% Year-over-Year to $2.53 Million and Up 94% From Previous Quarter; Files Form 10-Q for Q3 2026; Total Assets of $133.1 Million Include $100.4 Million Held in Trust by Sponsored SPAC PMGC Holdings Inc. [NASDAQ: ELAB] Reports Record Q3 Revenue, Up 785% Year-over-Year to $2.53 Million and Up 94% From Previous Quarter; Files Form 10-Q forbenzinga.com PMGC Holdings Completes Subscription For Common Shares In Orbit2Orbit; Financial Terms Not Disclosed PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company"), a diversified public holding company, announces that PMGC Capital LLC, the Company’s investment arm, has completed a subscription for…
benzinga.com PMGC Holdings Unit Northstrive Biosciences Completes Preclinical Study Evaluating EL-32 Both As A Standalone Treatment And In Combination With Semaglutide; Study Identifies Preliminary Lean-mass Finding At Highest Dose While Informing Future Preclinical Development Strategy PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced the completion of a preclinical study evaluating EL-32, an engineered probiotic candidate being developed by its wholly owned
